ViVac Appoints Keren Leshem as Chief Executive Officer

ViVac announced the appointment of Keren Leshem as Chief Executive Officer, marking a significant milestone in the company’s evolution from research-driven startup to emerging leader in RNA-based cancer immunotherapy.

Leshem, a World Economic Forum Technology Pioneer CEO, has been recognized by Forbes and Entrepreneur as one of the most influential voices in biotechnology. She brings over two decades of experience building and scaling clinical-stage life science companies and has a proven track record of translating breakthrough science into global impact.

At ViVac, she will lead the company’s next phase of growth, advancing the synthetic biology and lipid nanoparticle platform from preclinical development toward first-in-human studies. Under her leadership, ViVac aims to redefine how RNA can be used to safely and effectively combat cancer through precision immunotherapy.

“ViVac’s approach represents a paradigm shift in oncology — combining the intelligence of synthetic biology with the precision of nanomedicine,” said Leshem. “I’m honored to lead such an exceptional scientific team as we work to bring this innovation to patients who need it most.”